基础医学与临床 ›› 2026, Vol. 46 ›› Issue (9): 1213-1220.doi: 10.16352/j.issn.1001-6325.2026.09.1213

• 研究论文 • 上一篇    下一篇

补肺活血方剂通过调控SphK1/S1P通路减轻COPD模型大鼠肺组织炎性损伤

李晓颖1, 李晓丹2*, 李玉倩2, 李山山2, 李天歌2   

  1. 1.天津市第三中心医院分院 中医科,天津 300250;
    2.天津中医药大学第二附属医院 呼吸科,天津 300250
  • 收稿日期:2025-12-01 修回日期:2026-03-31 出版日期:2026-09-05 发布日期:2026-08-18
  • 通讯作者: *lixiaodan12230@163.com
  • 基金资助:
    天津市教委科研计划(2024ZD011)

Bufei-Huoxue formula (BFHX) alleviates pulmonary inflammatory injury in rat models with COPD by regulating the SphK1/S1P signaling pathway

LI Xiaoying1, LI Xiaodan2*, LI Yuqian2, LI Shanshan2, LI Tiange2   

  1. 1. Department of Traditional Chinese Medicine, Tianjin Third Central Hospital Branch, Tianjin 300250;
    2. Department of Respiratory Medicine, the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China
  • Received:2025-12-01 Revised:2026-03-31 Online:2026-09-05 Published:2026-08-18
  • Contact: *lixiaodan12230@163.com

摘要: 目的 探讨补肺活血方剂(BFHX)对慢性阻塞性肺疾病(COPD)大鼠肺组织炎性损伤的影响。方法 用气管内滴注脂多糖(LPS)联合烟熏法建立COPD大鼠模型。将大鼠随机分为对照(control)组、模型(model)组、阳性药物氨溴索(positive)组、补肺活血方剂低、高剂量(BFHX-L、BFHX-H)组、补肺活血方剂高剂量+SphK1/S1P通路激活剂(BFHX-H+PMA)组,另取8只健康大鼠作为对照(control)组。检测大鼠肺功能、ELISA检测肺泡灌洗液(BALF)中炎性因子水平,HE染色检测肺组织病理变化,阿利新蓝-过碘酸雪夫(AB-PAS)染色检测支气管黏液分泌;Masson染色检测肺组织纤维化;免疫组化法检测肺组织黏蛋白5ac(Muc5ac)蛋白表达;Western blot检测鞘氨醇激酶1(SphK1)、1-磷酸鞘氨醇(S1P)、α-平滑肌肌动蛋白(α-SMA)、Ⅰ型胶原蛋白(ColⅠ)、转化生长因子-β(TGF-β)蛋白表达。结果 与对照组比较,模型组大鼠肺功能下降、纤维化加重,BALF中肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和IL-8水平及肺组织支气管黏液分泌量、胶原容积分数、Muc5ac阳性表达、SphK1、S1P、α-SMA、ColⅠ和TGF-β蛋白表达量升高,IL-10水平降低(P<0.05);相较于模型组,BFHX处理组和positive组大鼠肺功能和组织病理损伤得到改善,BALF中TNF-α、IL-6和IL-8水平及肺组织支气管黏液分泌量、胶原容积分数、Muc5ac阳性表达、SphK1、S1P、α-SMA、ColⅠ和TGF-β蛋白表达量降低,IL-10水平升高(P<0.05);相较于BFHX-H组,BFHX-H+PMA组肺组织病理损伤加重、肺功能下降,BALF中TNF-α、IL-6和IL-8水平、肺组织支气管黏液分泌量、胶原容积分数、Muc5ac阳性表达、SphK1、S1P、α-SMA、ColⅠ和TGF-β蛋白表达量升高,IL-10水平降低(P<0.05)。结论 BFHX可减轻COPD大鼠气道黏液高分泌和肺纤维化,改善肺组织炎性损伤和肺功能,其作用机制可能与SphK1/S1P通路活性降低有关。

关键词: 补肺活血方剂(BFHX), 慢性阻塞性肺疾病, 气道黏液, 肺纤维化, SphK1/S1P通路

Abstract: Objective To investigate the effect of Bufei-Huoxue formula (BFHX) on inflammatory injury in the lung tissue of rat model with chronic obstructive pulmonary disease (COPD). Methods Rat model of COPD was established by endotracheal infusion of lipopolysaccharide (LPS) combined with smoking stimulation. Rats were randomly assigned into model group, positive drug ambroxol (positive) group, low- and high-dose BFHX (BFHX-L, BFHX-H) groups, and high-dose BFHX+SphK1/S1P pathway activator (BFHX-H+PMA) group. The control group consisted of 8 healthy rats. The lung function of rats was examined, and the level of inflammatory cytokines in bronchoalveolar lavage fluid (BALF) was measured by ELISA. The pathological changes of lung tissue were detected by HE staining, bronchial mucus secretion was measured by AB-PAS staining and pulmonary fibrosis was measured by Masson staining. The expression of Muc5ac protein in lung tissue was measured by immuno-histochemistry and the expression of SphK1,S1P,α-SMA,ColⅠ and TGF-β proteins was detected by Western blot. Results Compared with the control group, rats in the model groups exhibited decreased lung function and aggravated pulmonary fibrosis accompanied by elevated level of TNF-α,IL-6,and IL-8 in BALF, increased bronchial mucus secretion and collagen volume fraction,Muc5ac positive expression and protein expression level of SphK1,S1P,α-SMA,ColⅠ,and TGF-β in lung tissue, as well as a reduced level of IL-10(P<0.05). Compared with the model groups, the BFHX-treated group and positive group showed improved pulmonary function and alleviated histo-pathological damage of lung tissue. Additionally The level of TNF-α,IL-6,and IL-8 in BALF, bronchial mucus secretion in lung tissue, collagen volume fraction, positive expression of Muc5ac,as well as the protein expression of SphK1,S1P,α-SMA, ColⅠand TGF-β were all significantly decreased, while the level of IL-10 was markedly increased(P<0.05). Compared with BFHX-H group, the BFHX-H+PMA group exhibited aggravated histo-pathological damage and impaired pulmonary function in lung tissue. Furthermore, the levels of TNF-α,IL-6,and IL-8 in BALF,the amount of bronchial mucus secretion in lung tissue collagen volume fraction, the positive expression of Muc5ac,as well as the protein expression levels of SphK1,S1P,α-SMA,ColⅠ,and TGF-β were also significantly increased, but the level of IL-10 was markedly decreased(P<0.05). Conclusions BFHX alleviates airway mucus hyper-secretion and pulmonary fibrosis in COPD rat models and improve lung tissue inflammatory injury and lung function. Its mechanism of action potentially related to the reduction of SphK1/S1P pathway activity.

Key words: Bufei-Huoxue formula (BFHX), chronic obstructive pulmonary disease, airway mucus, pulmonary fibrosis, SphK1/S1P pathway

中图分类号: